Fredun Pharmaceuticals Limited has announced the strategic launch of "HORMONE RANGE PRODUCTS", a premium specialty therapeutics brand focused on longevity, hormone health, recovery science, and human performance solutions. The announcement was made on 15th May, 2026, under Regulation 30, marking the company's entry into a rapidly expanding, high-value healthcare segment driven by increasing global demand for preventive, performance-oriented, and precision-based therapeutics.

The hormone range products are built on a doctor-led, ethical, and evidence-backed pharmaceutical model, combining clinical credibility with a digital-first patient and doctor engagement ecosystem. The range is designed to address the growing shift from traditional disease management towards healthy lifespan optimization, preventive care, and advanced performance therapeutics.

Strategic Highlights

The launch encompasses several strategic dimensions that position Fredun Pharmaceuticals in the specialty therapeutics space. Key highlights of the initiative include:

• Strategic expansion into high-growth longevity and specialty hormone therapeutics
• Doctor-led and evidence-backed platform focused on clinical outcomes
• Premium positioning in hormone health, recovery science, and performance care
• Digital and pharma hybrid model enabling end-to-end patient engagement
• Focused on precision-driven, high-margin, and differentiated therapeutic categories
• Strengthening Fredun Pharmaceuticals' innovation-led specialty pharma portfolio
• The range will work in conjunction with the company's existing protein supplement range, enabling a more comprehensive approach towards preventive healthcare, wellness, and performance therapeutics

Initial Product Portfolio

The initial portfolio includes therapies and formulations across key hormone and performance therapeutic categories. The following table outlines the core product focus areas:

The platform is further supported by protocol-driven patient monitoring, doctor engagement, and direct-to-patient fulfillment capabilities designed to improve treatment continuity and patient adherence.

Core Business and Growth Drivers

The brand leverages Fredun Pharmaceuticals' established strengths in pharmaceutical formulation development, quality-focused manufacturing, and global distribution capabilities. The core business and growth drivers underpinning the launch are:

• Premium, science-driven therapeutic positioning
• Focus on hormone optimization and preventive healthcare
• Digital-led patient acquisition and retention strategy
• Specialised formulations with strong clinical orientation
• Direct-to-patient engagement and subscription-based continuity model
• Expansion into emerging high-growth healthcare categories

Management Commentary

Commenting on the development, Mr. Fredun Medhora, Managing Director, Fredun Pharmaceuticals Limited, stated: "The launch of our hormone range products represents a significant milestone in our journey towards building a more specialised and future-ready pharmaceutical portfolio. As we move up the value chain, our focus is on entering segments that demand high scientific rigor, clinical validation, and manufacturing excellence. This range reflects our vision by bringing together medical expertise and evidence-based formulations to create a credible presence in hormone and performance therapeutics."

About Fredun Pharmaceuticals Limited

Fredun Pharmaceuticals Limited is a healthcare and pharmaceuticals company offering a range of products, including antihypertensives, antidiabetic, antiretroviral drugs (ARVs), and narcotics. The company is also engaged in the manufacturing of dietary and herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products, along with animal healthcare products. The company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries, and Latin America. The following table summarises the company's key financial metrics for FY25:

Fredun Pharmaceuticals Limited convened a Board of Directors meeting on Friday, May 15, 2026, conducted through Video Conferencing (VC). The meeting was held in compliance with Regulation 30 of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, and the outcome was formally disclosed to BSE Limited.

Board Meeting Overview

The Board meeting commenced at 07:30 P.M. and concluded at 08:00 P.M. on May 15, 2026. The key business transacted during the session is outlined below:

Key Business Transacted

The sole agenda item addressed during the meeting was the review of the Monitoring Agency Report for the quarter ended March 31, 2026. The Board took note of the report as part of its statutory and regulatory obligations under the applicable SEBI listing regulations.

The disclosure was signed by Fredun Nariman Medhora, Managing Director, from Mumbai, and submitted to the Corporate Relationship Department of BSE Limited at Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.